For the quarter ended December 2024, Nektar Therapeutics (NKTR Quick QuoteNKTR - Free Report) reported revenue of $29.18 million, up 22.1% over the same period last year. EPS came in at $0.15, compared to -$0.22 in the year-ago quarter.

The reported revenue represents a surprise of -25.23% over the Zacks Consensus Estimate of $39.02 million. With the consensus EPS estimate being -$0.13, the EPS surprise was +215.38%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Nektar performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenue- Product sales: $12.87 million versus the eight-analyst average estimate of $9.76 million. The reported number represents a year-over-year change of +134.8%.
• Revenue- Non-cash royalty revenue related to sale of future royalties: $16.24 million versus $15.15 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a -10.1% change.
• Revenue- License, collaboration and other revenue: $0.06 million versus the four-analyst average estimate of $28.26 million. The reported number represents a year-over-year change of -81.5%.

View all Key Company Metrics for Nektar here>>>

Shares of Nektar have returned +23.5% over the past month versus the Zacks S&P 500 composite's -8.2% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.